Compare · BDX vs CODX
BDX vs CODX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Co-Diagnostics Inc. (CODX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and CODX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 6721.9x CODX ($7.7M).
- Over the past year, BDX is down 2.2% and CODX is down 86.7% - BDX leads by 84.5 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 8 for CODX).
- BDX has more recent analyst coverage (25 ratings vs 3 for CODX).
- Company
- Becton Dickinson and Company
- Co-Diagnostics Inc.
- Price
- $189.79-0.43%
- $1.23+0.00%
- Market cap
- $51.69B
- $7.7M
- 1M return
- +19.45%
- -39.26%
- 1Y return
- -2.22%
- -86.71%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 10
- 8
- Recent ratings
- 25
- 3
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Co-Diagnostics Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest CODX
- SEC Form S-3 filed by Co-Diagnostics Inc.
- Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
- SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.
- SEC Form 10-Q filed by Co-Diagnostics Inc.
- Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Co-Diagnostics Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Co-Diagnostics Inc.
- Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
- Co-Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast